On this episode of the Artificial Intelligence in Drug Discovery podcast, I speak with Sam Cooper, cofounder and CEO of Phenomic AI. Sam and his team use machine learning for automated image analysis to study cell biology and screen drugs. But that’s just the beginning.
Listen now to learn about Phenomic’s distinct approach to drug discovery, its use of machine learning for high content screening, and how they plan to scale from a technology company to a full stack biotech business: